<p>The embodiments provide prodrug compounds of Formulae I-XVII. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XVII that provides controlled release of an active agent. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an active agent from the prodrug so as to attenuate enzymatic cleavage of the prodrug.</p>
申请公布号
WO2012122422(A3)
申请公布日期
2014.04.24
申请号
WO2012US28367
申请日期
2012.03.08
申请人
SIGNATURE THERAPEUTICS, INC.;JENKINS, THOMAS E.;HUSFELD, CRAIG O.